Literature DB >> 8616082

Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome.

D I Marks1, E C Vonderheid, B W Kurz, R D Bigler, K Sinha, D A Morgan, A Sukman, P C Nowell, D S Haines.   

Abstract

Sézary syndrome is a leukaemic form of cutaneous T-cell lymphoma which presents with multiple cytogenetic abnormalities and responds poorly to chemotherapy. Because of the importance of the p53 tumour suppressor in maintaining genomic stability and in sensitizing transformed cells to DNA damaging agents, we looked for alternations which may affect p53 functions in 18 patients with Sézary syndrome. Cytogenetic analysis suggested frequent p53 gene inactivation since 6/18 patients had loss of one copy of 17p. However, single-strand conformational polymorphism (SSCP) revealed that p53 gene mutations are relatively rare, occurring in only two of 18 Sézary patients. Neither of these two patients was missing a copy of 17p. Possible abnormalities of p53 pathway function through mdm-2 over-expression were also investigated. Although all 18 patients had normal levels of mdm-2 RNA 4/18 over-expressed mdm-2 protein. One patient with advanced disease and the highest percentage of malignant cells overexpressed mdm-2 protein and possessed a nonsense p53 gene mutation. The five patients with abnormalities of p53 or mdm-2 were found to have significantly highest absolute lymphocyte counts and higher absolute numbers of Sézary cells (P=0-021 and 0.027 respectively). In summary, molecular alternations of 17p and potential p53 pathway abnormalities are a common event in Sézary syndrome and appear to be associated with more advanced disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616082     DOI: 10.1046/j.1365-2141.1996.439978.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target.

Authors:  Daniel Humme; Ahmed Haider; Markus Möbs; Hiroshi Mitsui; Mayte Suárez-Fariñas; Hanako Ohmatsu; Cyprienne Isabell Geilen; Jürgen Eberle; James G Krueger; Marc Beyer; Michael Hummel; Ioannis Anagnostopoulos; Wolfram Sterry; Chalid Assaf
Journal:  J Invest Dermatol       Date:  2015-04-07       Impact factor: 8.551

Review 2.  Aberrant responses of human lymphocytic neoplasms to cytokine regulation.

Authors:  P C Nowell; J S Moore
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

3.  Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.

Authors:  Qin Li; Yun Zhang; Adel K El-Naggar; Shunbin Xiong; Peirong Yang; James G Jackson; Gilda Chau; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2014-03-05       Impact factor: 5.852

4.  TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis.

Authors:  Peipei Xu; Xu Liu; Jian Ouyang; Bing Chen
Journal:  PLoS One       Date:  2017-04-03       Impact factor: 3.240

5.  TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.

Authors:  Audrey Gros; Elodie Laharanne; Marie Vergier; Martina Prochazkova-Carlotti; Anne Pham-Ledard; Thomas Bandres; Sandrine Poglio; Sabine Berhouet; Béatrice Vergier; Jean-Philippe Vial; Edith Chevret; Marie Beylot-Barry; Jean-Philippe Merlio
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.